Dyadic Announces Achieving Human Like Glycan Structures From Its Engineered C1 Cell Line

November 25, 2019 8:00 AM

High G0 Glycosylation Level Driving Program AccelerationJUPITER, FL / ACCESSWIRE / November 25, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, announced...

Read more

Biotech Showcase Returns for Twelfth Year, Expecting Record Levels of Attendance and Capital

November 21, 2019 8:00 AM

NEW YORK, NY, SAN FRANCISCO, CA and CARLSBAD, CA / ACCESSWIRE / November 21, 2019 / Biotech Showcase™ is the investor conference that drives the future of therapeutic innovation, digital medicine, and international collaboration. Highlights from this year's programming include workshops and panels on emerging technologies, advances in therapeutic discovery and development, and predictions on the 2020 investment landscape. With more...

Read more

Experion Holdings Ltd. Increases Distribution: Adds the Province of Manitoba, Alberta and Yukon to its Cannabis Supply Distribution Network

November 20, 2019 8:45 AM

VANCOUVER, BC / ACCESSWIRE / November 20, 2019 / Experion Holdings Ltd. (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31), is pleased to announce that its wholly-owned subsidiary Experion Biotechnologies Inc. ("Experion or "the Company''), a Health Canada licensed cultivator and processor of Cannabis, has been accepted by the Manitoba Liquor and Lotteries Corporation ("MBLL"), Alberta Gaming, Liquor & Cannabis and the Yukon...

Read more

Avalon GloboCare to Present at the 12th Annual LD Micro Main Event on December 10th

November 20, 2019 8:30 AM

FREEHOLD, NJ / ACCESSWIRE / November 20, 2019 / Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of cell-based technologies and therapeutics, today announced that management will present at the 12th Annual LD Micro Main Event institutional investor conference being held on December 10-12, 2019 at the Luxe Sunset Bel Air Hotel in Bel Air, California. David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon...

Read more

Hancock Jaffe Medical Team to Make Presentations at 46th Annual VEITH Vascular Symposium November 19 to November 23 in New York City

November 19, 2019 8:31 AM

VenoValve and CoreoGraft to be Discussed at VEITH IRVINE, CA / ACCESSWIRE / November 19, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's VenoValve study in Colombia, and Dr. Marc H. Glickman, HJLI's Senior Vice President and Chief Medical Officer, will be making...

Read more

International Stem Cell Corporation Announces Financial Results for the Three and Nine-Months ended September 30, 2019

November 15, 2019 9:00 PM

CARLSBAD, CA / ACCESSWIRE / November 15, 2019 / International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today announced operating results for the three and nine months ended September 30, 2019. "As we mentioned before we completed the...

Read more

Hancock Jaffe Enrolls and Successfully Implants Tenth VenoValve Patient

November 15, 2019 1:00 PM

Initial Implantation Phase for First-in-Man Study Now Completed IRVINE, CA / ACCESSWIRE / November 15, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI)(NASDAQ:HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that it has enrolled and successfully implanted the 10th patient to complete the initial implantation phase of the first-in-man VenoValve study being conducted in Colombia. The surgery...

Read more

Taiwan Announced the Application of Cell Therapy, The Value of The Medical Industry was Improved

November 15, 2019 11:40 AM

Taiwan has top cell technology, and Guang-Li Biomedicine and Taipei Medical University Hospital have passed legal review in November, 2019. TAIPEI, TAIWAN / ACCESSWIRE / November 15, 2019 / In September last year, Taiwan announced the application method for cell therapy. Up to now, 27 medical institutions and 80 cell therapy applications are awaiting review, which is expected to increase medical output. Among them, Taipei Medical University...

Read more

Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update

November 15, 2019 8:30 AM

- Company ramps up activities to execute XCART's preclinical and regulatory strategy - - Cash runway expected to fund Company through preclinical advancements towards IND filing - FRAMINGHAM, MA / ACCESSWIRE / November 15, 2019 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART, a personalized chimeric antigen receptor T cell...

Read more

Pieris Pharmaceuticals Announces Asthma-focused Translational Research Collaboration with the University of Pittsburgh

November 15, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / November 15, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced a research collaboration between the Company and the labs of University of Pittsburgh Professors Sally Wenzel, MD, and Anuradha Ray, PhD, focused on...

Read more

Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

November 14, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / November 14, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences: Jefferies 2019 London Healthcare...

Read more

avateramedical GmbH: CE Mark for avatera(R), the First German System for Robot-Assisted, Minimally Invasive Surgery, Setting the Foundation for Strategic Growth Plans

November 14, 2019 5:00 AM

CE Mark for avatera(R), the First German System for Robot-Assisted, Minimally Invasive Surgery, Setting the Foundation for Strategic Growth Plans - Confirmation of safety and performance capability for all components of the avatera system enables European market entry - New, competitive player in the strongly growing robot-assisted surgery market - Introduction of the avatera system into everyday clinical practice in Europe and a...

Read more

Dyadic Reports Third Quarter 2019 Results And Recent Developments

November 13, 2019 4:00 PM

New Fully Funded Research Collaboration with Leading Animal Health Company; Fifth Partnership in Animal SectorExpansion of Existing Research Collaboration to Express an Additional Protein with Major Animal Health CompanyNew Fully Funded Research Collaboration to Express Proteins with Top Tier Pharmaceutical CompanyContinued Progress with Existing Scientific PartnersJoined Russell Microcap® IndexJUPITER, FL / ACCESSWIRE / November 13, 2019 /...

Read more

Cantabio Announces Publication of Novel Study Demonstrating the Importance of the DJ-1 Protein in the Onset and Pathology of Alzheimer's and Parkinson's disease

November 13, 2019 8:30 AM

Study shows that DJ-1 misfolds to form b-sheet structured fibrillar aggregates that co-localize with pathological amyloid deposits characteristic of Parkinson's and Alzheimer's disease in patients' post-mortem brain tissues PALO ALTO, CA / ACCESSWIRE / November 13, 2019 / Cantabio Pharmaceuticals, Inc. ("Cantabio" or the "Company"), a preclinical stage pharmaceutical company developing disease modifying...

Read more

Frelii Announces Master License Agreement with Systemic Formulations

November 12, 2019 9:00 AM

LEHI, UTAH / ACCESSWIRE / November 12, 2019 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or the "Company"), a biotechnology company working to commercialize its patent-pending DNA gene sequencing artificial intelligence technology, announced today it has signed a Master License Agreement ("Agreement) with Systemic Formulations Inc. ("Customer"). "We believe the efficacy of our genome discovery artificial...

Read more

Pieris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

November 11, 2019 7:00 AM

Company to Host an Investor Conference Call On Monday, November 11, 2019 At 8:00 AM EST BOSTON, MA / ACCESSWIRE / November 11, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today reported its financial results for the third quarter of 2019 ended...

Read more

Pieris Pharmaceuticals Presents Data Demonstrating Monotherapy Clinical Benefit with 4-1BB/HER2 Bispecific PRS-343 in Phase 1 Escalation Study at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting

November 9, 2019 12:00 PM

BOSTON, MA / ACCESSWIRE / November 9, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the presentation of data from the phase 1 dose-escalation monotherapy study of PRS-343, a 4-1BB/HER2 bispecific for the treatment of HER2-positive solid...

Read more

ReShape Lifesciences to Host Third Quarter 2019 Conference Call on November 14, 2019

November 7, 2019 5:30 PM

SAN CLEMENTE, CA / ACCESSWIRE / November 7, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it will host a conference call to discuss financial results for the third quarter of 2019 on Thursday, November 14, 2019 at 1:30 PM Pacific Time. Individuals interested in listening to the conference call may do so by...

Read more

GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update

November 7, 2019 2:05 PM

The Underlying Value of GeoVax, and the Promise of the Technology...A Comprehensive Review of GeoVax's Various Development Programs ATLANTA, GA / ACCESSWIRE / November 7, 2019 / GeoVax Labs, Inc. (OTCQB:GOVX), a biotechnology company developing human immunotherapies and vaccines, today announced its financial results for the quarter ended September 30, 2019 and provided an update on its corporate development progress. View full...

Read more

Pieris Pharmaceuticals to Host R&D Event

November 7, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / November 7, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that the Company will host an R&D event in New York on Tuesday, November 19, 2019 from 12:00 - 3:30 PM EST. The R&D event will feature...

Read more